ENOVIS CORP (ENOV) Stock Fundamental Analysis
NYSE:ENOV - New York Stock Exchange, Inc. - US1940141062 - Common Stock - Currency: USD
We assign a fundamental rating of 4 out of 10 to ENOV. ENOV was compared to 191 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of ENOV while its profitability can be described as average. ENOV has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
ENOV had positive earnings in the past year.
ENOV had a positive operating cash flow in the past year.
The reported net income has been mixed in the past 5 years: ENOV reported negative net income in multiple years.
Of the past 5 years ENOV 4 years had a positive operating cash flow.
1.2 Ratios
ENOV's Return On Assets of -17.49% is in line compared to the rest of the industry. ENOV outperforms 53.40% of its industry peers.
ENOV has a Return On Equity (-32.22%) which is in line with its industry peers.
ENOV's Return On Invested Capital of 0.23% is fine compared to the rest of the industry. ENOV outperforms 65.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.49% | ||
| ROE | -32.22% | ||
| ROIC | 0.23% |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Operating Margin of ENOV (0.58%) is better than 65.97% of its industry peers.
ENOV's Operating Margin has declined in the last couple of years.
ENOV has a Gross Margin of 56.87%. This is comparable to the rest of the industry: ENOV outperforms 52.88% of its industry peers.
In the last couple of years the Gross Margin of ENOV has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 0.58% | ||
| PM (TTM) | N/A | ||
| GM | 56.87% |
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
2. Health
2.1 Basic Checks
ENOV has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
ENOV has more shares outstanding than it did 1 year ago.
ENOV has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, ENOV has a worse debt to assets ratio.
2.2 Solvency
ENOV has an Altman-Z score of 1.04. This is a bad value and indicates that ENOV is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.04, ENOV is in line with its industry, outperforming 54.45% of the companies in the same industry.
ENOV has a Debt/Equity ratio of 0.51. This is a neutral value indicating ENOV is somewhat dependend on debt financing.
ENOV has a Debt to Equity ratio (0.51) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.04 |
ROIC/WACC0.03
WACC8.83%
2.3 Liquidity
ENOV has a Current Ratio of 2.17. This indicates that ENOV is financially healthy and has no problem in meeting its short term obligations.
ENOV has a worse Current ratio (2.17) than 60.21% of its industry peers.
ENOV has a Quick Ratio of 1.13. This is a normal value and indicates that ENOV is financially healthy and should not expect problems in meeting its short term obligations.
ENOV has a worse Quick ratio (1.13) than 70.68% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.17 | ||
| Quick Ratio | 1.13 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 17.92% over the past year.
ENOV shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -16.18% yearly.
The Revenue has grown by 23.46% in the past year. This is a very strong growth!
ENOV shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -8.73% yearly.
EPS 1Y (TTM)17.92%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%24.05%
Revenue 1Y (TTM)23.46%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%23.29%
3.2 Future
The Earnings Per Share is expected to grow by 23.19% on average over the next years. This is a very strong growth
Based on estimates for the next years, ENOV will show a quite strong growth in Revenue. The Revenue will grow by 8.87% on average per year.
EPS Next Y14.79%
EPS Next 2Y14.8%
EPS Next 3Y14.97%
EPS Next 5Y23.19%
Revenue Next Year5.32%
Revenue Next 2Y5.82%
Revenue Next 3Y6.17%
Revenue Next 5Y8.87%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 11.38, which indicates a very decent valuation of ENOV.
ENOV's Price/Earnings ratio is rather cheap when compared to the industry. ENOV is cheaper than 93.19% of the companies in the same industry.
ENOV's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.63.
The Price/Forward Earnings ratio is 9.92, which indicates a very decent valuation of ENOV.
ENOV's Price/Forward Earnings ratio is rather cheap when compared to the industry. ENOV is cheaper than 95.29% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 20.85. ENOV is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.38 | ||
| Fwd PE | 9.92 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ENOV is valued cheaper than 88.48% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 10.46 |
4.3 Compensation for Growth
ENOV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as ENOV's earnings are expected to grow with 14.97% in the coming years.
PEG (NY)0.77
PEG (5Y)N/A
EPS Next 2Y14.8%
EPS Next 3Y14.97%
5. Dividend
5.1 Amount
No dividends for ENOV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
32.21
+0.25 (+0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners112.11%
Inst Owner Change0.09%
Ins Owners0.96%
Ins Owner Change8.18%
Market Cap1.84B
Analysts83.53
Price Target66.81 (107.42%)
Short Float %9.91%
Short Ratio5.46
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.6%
Min EPS beat(2)4.97%
Max EPS beat(2)16.23%
EPS beat(4)4
Avg EPS beat(4)6.3%
Min EPS beat(4)1.38%
Max EPS beat(4)16.23%
EPS beat(8)8
Avg EPS beat(8)7.78%
EPS beat(12)12
Avg EPS beat(12)9.15%
EPS beat(16)15
Avg EPS beat(16)7.61%
Revenue beat(2)0
Avg Revenue beat(2)-1.33%
Min Revenue beat(2)-1.74%
Max Revenue beat(2)-0.93%
Revenue beat(4)1
Avg Revenue beat(4)-1.09%
Min Revenue beat(4)-2.12%
Max Revenue beat(4)0.45%
Revenue beat(8)4
Avg Revenue beat(8)-0.47%
Revenue beat(12)5
Avg Revenue beat(12)-0.98%
Revenue beat(16)6
Avg Revenue beat(16)-12.25%
PT rev (1m)0%
PT rev (3m)-0.76%
EPS NQ rev (1m)0.12%
EPS NQ rev (3m)13.27%
EPS NY rev (1m)0.9%
EPS NY rev (3m)1.32%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)2.62%
Revenue NY rev (1m)0.04%
Revenue NY rev (3m)-0.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.38 | ||
| Fwd PE | 9.92 | ||
| P/S | 0.87 | ||
| P/FCF | N/A | ||
| P/OCF | 16.21 | ||
| P/B | 0.72 | ||
| P/tB | N/A | ||
| EV/EBITDA | 10.46 |
EPS(TTM)2.83
EY8.79%
EPS(NY)3.25
Fwd EY10.09%
FCF(TTM)-1.18
FCFYN/A
OCF(TTM)1.99
OCFY6.17%
SpS36.9
BVpS44.87
TBVpS-7.84
PEG (NY)0.77
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.49% | ||
| ROE | -32.22% | ||
| ROCE | 0.29% | ||
| ROIC | 0.23% | ||
| ROICexc | 0.23% | ||
| ROICexgc | 0.85% | ||
| OM | 0.58% | ||
| PM (TTM) | N/A | ||
| GM | 56.87% | ||
| FCFM | N/A |
ROA(3y)-6.18%
ROA(5y)-3.42%
ROE(3y)-11.19%
ROE(5y)-6.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-45.54%
ROICexc growth 3YN/A
ROICexc growth 5Y-43.8%
OM growth 3YN/A
OM growth 5Y-43.59%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.41%
GM growth 5Y6.07%
F-Score3
Asset Turnover0.45
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.51 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 4.41 | ||
| Cap/Depr | 63.45% | ||
| Cap/Sales | 8.57% | ||
| Interest Coverage | 0.24 | ||
| Cash Conversion | 38.21% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.17 | ||
| Quick Ratio | 1.13 | ||
| Altman-Z | 1.04 |
F-Score3
WACC8.83%
ROIC/WACC0.03
Cap/Depr(3y)55.91%
Cap/Depr(5y)50.8%
Cap/Sales(3y)7.49%
Cap/Sales(5y)6.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.92%
EPS 3Y-23.78%
EPS 5Y-16.18%
EPS Q2Q%24.05%
EPS Next Y14.79%
EPS Next 2Y14.8%
EPS Next 3Y14.97%
EPS Next 5Y23.19%
Revenue 1Y (TTM)23.46%
Revenue growth 3Y13.9%
Revenue growth 5Y-8.73%
Sales Q2Q%23.29%
Revenue Next Year5.32%
Revenue Next 2Y5.82%
Revenue Next 3Y6.17%
Revenue Next 5Y8.87%
EBIT growth 1Y-39.31%
EBIT growth 3YN/A
EBIT growth 5Y-48.51%
EBIT Next Year81.17%
EBIT Next 3Y30.6%
EBIT Next 5Y28.11%
FCF growth 1Y-626.52%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-15.92%
OCF growth 3Y-31.69%
OCF growth 5Y-2.82%